A bivalent inactivated vaccine of avian nasal and tracheal avian bacillus a/b serotype

A bivalent inactivated vaccine and serotype technology, which is applied in the direction of antibacterial drugs, bacterial antigen components, emulsion delivery, etc., can solve the problem of unclear relationship between pathogenicity and serotype

Active Publication Date: 2020-07-14
何诚 +3
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the relationship between pathogenicity and serotype in different hosts is not clear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A bivalent inactivated vaccine of avian nasal and tracheal avian bacillus a/b serotype
  • A bivalent inactivated vaccine of avian nasal and tracheal avian bacillus a/b serotype
  • A bivalent inactivated vaccine of avian nasal and tracheal avian bacillus a/b serotype

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] The identification of embodiment 1 nasal trachea ornithosis and the preparation of inactivated vaccine

[0035] 1. Materials

[0036] Seed production strains: ORT-SD (type B), ORT-98 (type A) were isolated and identified from our research group;

[0037]Attacking strain: ORT-98, serotype A, donated by researcher Chen Xiaoling of Beijing Academy of Agriculture and Forestry;

[0038] Adjuvant: No. 10 light white oil: purchased from Hangzhou Refinery of Sinopec Group;

[0039] Water-soluble β-1,3 / 1,6 glucan: purchased from Angel Yeast Co., Ltd., with a content of 90%.

[0040] Poloxamer 407: purchased from BASF (China) Co., Ltd.

[0041] 2. Method

[0042] Vaccine antigen preparation: the two strains of avian nasal trachea aviophilum seed bacteria ORT-SD and ORT-98 strains of the present invention are first biochemically identified, and the results are as follows: figure 1 As shown, the ORT isolates were positive for glycosides such as glucose, lactose, fructose, and ...

Embodiment 2

[0078] Example 2 Screening of nasal and tracheal avian bacilli immune adjuvants

[0079] This example aims to use white oil and / or β-1,3 / 1,6 glucan as an immune adjuvant to emulsify with nasal and tracheal A. immune efficacy.

[0080] 1. Materials

[0081] 1.1 Strains and experimental animals

[0082] Seed production strains: ORT-SD (type B), ORT-98 (type A) were isolated and identified from our research group;

[0083] Attacking strain: ORT-98, serotype A, donated by researcher Chen Xiaoling of Beijing Academy of Agriculture and Forestry;

[0084] Experimental animals: 70 3-week-old SPF chickens, purchased from Beijing Weitong Meria Experimental Animal Co., Ltd.

[0085] 1.2 Main reagents and kits

[0086] Chicken cytokine ELISA antibody detection kit: purchased from U.S. Kingfisher Inc;

[0087] ORT antibody detection ELISA kit, purchased from American IDEXX company;

[0088] Control group vaccine Nobilis OR Inac: purchased from Intervet Company in the Netherlands, ma...

Embodiment 3

[0134] Example 3 The immune protection test of nasal trachea ornithosis to ducks

[0135] This example aims to evaluate the immune efficacy of the ORT bivalent inactivated oil emulsion vaccine prepared with white oil + dextran as an adjuvant on ducks.

[0136] 1. Materials

[0137] 1.1 Reagents and media:

[0138] 5% sheep blood agar plate or chocolate agar plate and blood agar medium: purchased from Beijing Guangda Hengyi Technology Co., Ltd.;

[0139] Control group vaccine: purchased from Israel ABIC Company, mainly containing ORT of three serotypes A, B, and C.

[0140] 1.2 Experimental animals: 40 1-day-old healthy Peking ducks, the breed of Beijing Jinxing ducks, were tested negative for avian bacilli in the nose and trachea, and were purchased from the duck farm of Nankou Farm, Beijing.

[0141] 1.3 strains:

[0142] Attacking strain: ORT-98, serotype A, donated by researcher Chen Xiaoling of Beijing Academy of Agriculture and Forestry;

[0143] Attacking strain: OR...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of immunology, and particularly discloses a poultry ornithobacterium rhinotracheale vaccine. The vaccine is prepared by taking isolated strains of two main epidemicserotypes of ornithobacterium rhinotracheale as antigens, culturing with a blood bouillon culture-medium, then inactivating by formaldehyde, mixing the antigens of the two serotypes at a ratio of 1 to1, then adding poloxamer with volume being 1 to 5 percent of that of the liquid antigens and beta glucan with volume being 1 to 4 percent of that of the liquid antigens to prepare a water phase, finally emusifying according to a ratio of the water phase to an oil phase being 4 to 6. The vaccine provided by the invention can be used for preventing symptoms such as respiratory diseases caused by currently epidemic poultry ornithobacterium rhinotracheale, slow growth and egg-laying decrease.

Description

technical field [0001] The invention relates to the field of immunology, in particular to an avian nasal and tracheal avian bacillus vaccine. Background technique [0002] Rhinotracheitis ornithosis is an acute, highly contagious respiratory infectious disease caused by Ornithobacterium rhinotracheale (ORT), mainly infecting broiler chickens and turkeys, manifested as dyspnea, growth retardation, egg production rate decline and high mortality. Necropsy showed unilateral or bilateral fibrinous suppurative pneumonia and air sacculitis, and 70% broiler respiratory diseases were associated with ORT infection. ORT was first isolated in 1981 by German scholars from 5-week-old turkeys suffering from facial swelling and severe air sacculitis. Later, Germany (1996), Israel (1997), South Africa (1996), Israel (1997), and the United Kingdom (1997) , the Netherlands (1997), Belgium (2001), Brazil (2003), Canada (1999), France (1998), and the United States (1997) have successively repo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/107A61K39/116A61K39/02A61P31/04A61P11/00
Inventor 何诚李佳沈志强曲光刚
Owner 何诚
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap